Join us for the official launch of DiMe’s Integrated Evidence Plans (IEP) resources, designed to help you overcome key challenges in evidence generation and commercial adoption of digital health technologies (DHTs)!
Join us for our launch, “Unlocking impact through investment: Building the business case for digital endpoints,” on Mar. 26 at 11 a.m. ET. Learn how new resources support you in measuring ROI and building your business case for digital endpoints.
Net financial benefits of digital endpoints publication in Clinical and Translational Science
Date/Time
October 16, 2024
Discussion Topic
Digital measures offer the clinical trials community unparalleled insights into people’s real-life experiences, enhancing our understanding of numerous conditions. So, why haven’t we implemented digital endpoints on a larger scale?
Findings from research conducted by DiMe, Tufts Center for the Study of Drug Development, Johnson & Johnson, Roche, Genentech, UCB, Bayer, Takeda, and MindMed, now published in the Journal of Clinical & Translational Science, showcase evidence of significant cost reductions and financial benefits tied to leveraging digital endpoints in trials.
